Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
232
-
Total 13F shares, excl. options
-
65.4M
-
Shares change
-
-2.4M
-
Total reported value, excl. options
-
$6.23B
-
Value change
-
-$249M
-
Put/Call ratio
-
1.19
-
Number of buys
-
115
-
Number of sells
-
-135
-
Price
-
$95.35
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2021
305 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q2 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 232 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.4M shares
of 96M outstanding shares and own 68.14% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (11M shares), VANGUARD GROUP INC (5.67M shares), Capital International Investors (5.46M shares), Capital Research Global Investors (4.57M shares), FEDERATED HERMES, INC. (3.85M shares), BlackRock Inc. (3.49M shares), Capital World Investors (2.77M shares), Clearbridge Investments, LLC (2.37M shares), ALKEON CAPITAL MANAGEMENT LLC (1.91M shares), and CITADEL ADVISORS LLC (1.86M shares).
This table shows the top 232 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.